UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-41614 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 84-1966887 (Sta ...

Exhibit 99.1 Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update • Pivotal Advance-HTN Trial – The ongoing Advance-HTN trial is evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), when used as an add-on therapy to a standardized background treatment of two or three antihypertensive medications. • Pivotal Launch-HTN Phase 3 Trial – The Company's second ongoing pivotal trial of ...

Minji Kim, PhD. Chief Business Officer 20+ years of experience: Affamed, Jounce, Curis, Hoffman-LaRoche, Genentech Cindy Berejikian Balance sheet supports activities to execute on upcoming milestones | --- | --- | --- | |------------------------------------------------------------------|-------|-------| | | | | | | | | | Targeting Aldosterone in the Treatment of Cardiorenal Diseases | | | | Mar ch 2024 | | | We caution you that this presentation contains forward-looking statements. All statements other than ...

Mineralys Therapeutics, Inc. (OTCQX:HCHDF) Q4 2023 Earnings Conference Call March 21, 2024 8:30 AM ET Company Participants Daniel Ferry - IR, LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer and Chief Business Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore ISI Mary Kate - Bank of America Seamus Fernandez - Guggenheim Securities Operator Welcome to the Mineralys Therapeutics Fourth Quarter and Full Year 2023 Con ...

Exhibit 99.1 Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update – Enrollment in the two pivotal trials of lorundrostat for the treatment of uHTN or rHTN is on track, with topline data expected for Advance-HTN trial in Q4 2024 and Launch-HTN trial in 2H 2025 – – Explore-CKD Phase 2 trial, a study for lorundrostat in hypertensive patients with stage 2-3b CKD on track for Q4 2024 to Q1 2025 topline data – – Conference call today at 8:30 a.m. ET – • ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission file number 001-41614 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdic ...

Mineralys Therapeutics Inc. (NASDAQ:MLYS) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer and Chief Business Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore ISI Greg Harrison - Bank of America Jack Padovano - Stifel Seamus Fernandez - Guggenheim Securities Mohit Bansal - Wells Fargo Operator Good afternoon, ladies and ...

– On track to initiate planned Phase 3 pivotal Launch-HTN trial of lorundrostat to treat patients with uncontrolled or resistant hypertension in 2H 2023 – – Conference call today at 4:30 p.m. ET – "The third quarter was productive for Mineralys with ongoing progress in our clinical development of lorundrostat, the publication of our proof-of-concept study, Target-HTN, in the Journal of the American Medical Association and the addition of two new Board members. We have finalized the designs of Launch-HTN and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-41614 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 84-1966887 ...

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q2 2023 Results Conference Call August 7, 2023 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer and Chief Business Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore Greg Harrison - Bank of America Mohit Bansal - Wells Fargo Rich Law - Credit Suisse Operator Greetings, and welcome to the Mineralys Second Quarter 2023 Earnings Cal ...